Australia markets closed

Calyxt, Inc. (CLXT)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.3702-0.0598 (-13.91%)
As of 03:37PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close0.4300
Open0.4400
Bid0.3630 x 1100
Ask0.3700 x 2200
Day's range0.3600 - 0.4550
52-week range0.1250 - 1.5700
Volume927,665
Avg. volume2,004,137
Market cap18.082M
Beta (5Y monthly)1.76
PE ratio (TTM)N/A
EPS (TTM)-0.6410
Earnings date01 Mar 2023 - 06 Mar 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est5.50
  • GlobeNewswire

    Calyxt and Cibus Announce the Signing of a Definitive Merger Agreement

    NEW YORK, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its gene editing platform to deliver life-saving cell and gene therapies, announced today that Cibus Global LLC, a Delaware limited liability company (“Cibus”), and Calyxt, Inc. (NASDAQ: CLXT) (“Calyxt”), announced that Calyxt and Calypso Merger Subsidiary, LLC, a Delaware limited liability company and wholly-owned subsidiary of Calyxt, entered into an Agree

  • PR Newswire

    Calyxt and Cibus Announce Definitive Merger Agreement to Create Industry-Leading Precision Gene Editing and Trait Licensing Company

    Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, and Cibus, a leader in precision gene editing in agriculture, today announced that both companies have entered into a definitive merger agreement under which Calyxt and Cibus will merge in an all-stock transaction. The merger will create a new industry-leading company that combines the two pioneers in agriculture-based gene editing and establishes one of the world's most sophisticated facilities for trait development and next-

  • PR Newswire

    Calyxt Achieves Phase 1 Milestone in Collaboration Agreement to Develop Alternative to Palm Oil

    Calyxt, Inc. (NASDAQ: CLXT), a plant-based synthetic biology company announced today that it has successfully completed the first phase in its research collaboration agreement with a leading global food ingredient manufacturer based in Asia to develop an improved soybean capable of producing an oil as a commercial alternative to palm oil.